BACKGROUND: Mounting evidence suggests that compromised neurocognitive function is a central feature of schizophrenia. There are, however, schizophrenia patients with a normal neuropsychological (NP) performance, but estimates of the proportion of NP normal patients vary considerably between studies. Neurocognitive dysfunction is also a characteristic of other psychotic disorders, yet there are inconsistencies in the literature regarding the similarity to impairments in schizophrenia. NP normality in psychotic affective disorders has not been systematically studied. METHODS: Data came from the Suffolk County Mental Health Project, an epidemiological study of first-admission patients with psychotic disorders. Respondents with a diagnosis of schizophrenia (N = 94) or schizoaffective disorder (N = 15), bipolar disorder (N = 78), and major depressive disorder (N = 48) were administered a battery of NP tests assessing 8 cognitive domains 2 years after index admission. Patients' performance profile was compared, and their NP status was classified based on 3 previously published criteria that vary in their stringency. RESULTS: The 4 diagnostic groups had comparable NP performance profile patterns. All groups demonstrated impairments in memory, executive functions, and attention and processing speed. However, schizophrenia patients were more impaired than the other groups on all cognitive domains. Results were not attenuated when IQ was controlled. Prevalence of NP normality ranged between 16% and 45% in schizophrenia, 20% and 33% in schizoaffective disorder, 42% and 64% in bipolar disorder, and 42% and 77% in depression, depending on the criterion employed. CONCLUSIONS: Evidence suggests that differences in NP performance between schizophrenia and psychotic affective disorders are largely quantitative. NP impairment is also common in psychotic affective disorders. A significant minority of schizophrenia patients are NP normal.
BACKGROUND: Mounting evidence suggests that compromised neurocognitive function is a central feature of schizophrenia. There are, however, schizophreniapatients with a normal neuropsychological (NP) performance, but estimates of the proportion of NP normal patients vary considerably between studies. Neurocognitive dysfunction is also a characteristic of other psychotic disorders, yet there are inconsistencies in the literature regarding the similarity to impairments in schizophrenia. NP normality in psychotic affective disorders has not been systematically studied. METHODS: Data came from the Suffolk County Mental Health Project, an epidemiological study of first-admission patients with psychotic disorders. Respondents with a diagnosis of schizophrenia (N = 94) or schizoaffective disorder (N = 15), bipolar disorder (N = 78), and major depressive disorder (N = 48) were administered a battery of NP tests assessing 8 cognitive domains 2 years after index admission. Patients' performance profile was compared, and their NP status was classified based on 3 previously published criteria that vary in their stringency. RESULTS: The 4 diagnostic groups had comparable NP performance profile patterns. All groups demonstrated impairments in memory, executive functions, and attention and processing speed. However, schizophreniapatients were more impaired than the other groups on all cognitive domains. Results were not attenuated when IQ was controlled. Prevalence of NP normality ranged between 16% and 45% in schizophrenia, 20% and 33% in schizoaffective disorder, 42% and 64% in bipolar disorder, and 42% and 77% in depression, depending on the criterion employed. CONCLUSIONS: Evidence suggests that differences in NP performance between schizophrenia and psychotic affective disorders are largely quantitative. NP impairment is also common in psychotic affective disorders. A significant minority of schizophreniapatients are NP normal.
Authors: Christopher M Wilk; James M Gold; Robert P McMahon; Katherine Humber; Virginia N Iannone; Robert W Buchanan Journal: Neuropsychology Date: 2005-11 Impact factor: 3.295
Authors: David J Schretlen; Nicola G Cascella; Stephen M Meyer; Lisle R Kingery; S Marc Testa; Cynthia A Munro; Ann E Pulver; Paul Rivkin; Vani A Rao; Catherine M Diaz-Asper; Faith B Dickerson; Robert H Yolken; Godfrey D Pearlson Journal: Biol Psychiatry Date: 2006-12-11 Impact factor: 13.382
Authors: David C Glahn; Carrie E Bearden; Marcela Barguil; Jennifer Barrett; Abraham Reichenberg; Charles L Bowden; Jair C Soares; Dawn I Velligan Journal: Biol Psychiatry Date: 2007-06-01 Impact factor: 13.382
Authors: Pascal Missonnier; François R Herrmann; Adriano Zanello; Maryse Badan Bâ; Logos Curtis; Diana Canovas; Fabrice Chantraine; Jonas Richiardi; Panteleimon Giannakopoulos; Marco C G Merlo Journal: J Psychiatry Neurosci Date: 2012-02 Impact factor: 6.186
Authors: Philip D Harvey; Robert K Heaton; William T Carpenter; Michael F Green; James M Gold; Michael Schoenbaum Journal: Schizophr Res Date: 2012-04-13 Impact factor: 4.939
Authors: Suzanne N Avery; Lisa E Williams; Austin A Woolard; Stephan Heckers Journal: Eur Arch Psychiatry Clin Neurosci Date: 2013-09-11 Impact factor: 5.270
Authors: Eva Velthorst; Eric C Meyer; Anthony J Giuliano; Jean Addington; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Larry J Seidman Journal: Schizophr Res Date: 2018-08-02 Impact factor: 4.939
Authors: Rosa Ayesa-Arriola; Jose Manuel Rodríguez-Sánchez; Rocío Pérez-Iglesias; Roberto Roiz-Santiáñez; Obdulia Martínez-García; Jose Sánchez-Moreno; Rafael Tabarés-Seisdedos; Jose L Vázquez-Barquero; Benedicto Crespo-Facorro Journal: Psychopharmacology (Berl) Date: 2013-03-02 Impact factor: 4.530